Gene therapy data whipsaws
BEAM is dropping violently despite reporting durable clinical data for its BEAM-302 gene therapy, as investors focus on commercialization uncertainty and valuation concerns rather than the positive trial results.
Sources: https://allsci.com/news/clinical-trials/alpha-1-antitrypsin-gene-therapy-beams-base/, https://seekingalpha.com/news/beam-updates-phase-12
Previous verdicts for BEAM
- AI Search: Law Firm Investigation Adds Modest Overhang for BEAM — 2026-10-08
- ARK Buying Fuels BEAM Spike — 2026-09-22
- Safety jitters hit gene editing — 2026-09-10
- Gene therapy data whipsaws — 2026-09-08
- Gene therapy data disappoints — 2026-09-08
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works